Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson’s Disease: The International Linked Clinical Trials Initiative

In 2011, the UK medical research charity Cure Parkinson’s set up the international Linked Clinical Trials (iLCT) committee to help expedite the clinical testing of potentially disease modifying therapies for Parkinson’s disease (PD). The first committee meeting was held at the Van Andel Institute in...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Parkinson's disease 2024-01, Vol.14 (4), p.657-666
Main Authors: Wyse, Richard K., Isaacs, Tom, Barker, Roger A., Cookson, Mark R., Dawson, Ted M., Devos, David, Dexter, David T., Duffen, Joy, Federoff, Howard, Fiske, Brian, Foltynie, Thomas, Fox, Susan, Greenamyre, J. Timothy, Kieburtz, Karl, Kordower, Jeffrey H., Krainc, Dimitri, Matthews, Helen, Moore, Darren J., Mursaleen, Leah, Schwarzschild, Michael A., Stott, Simon R.W., Sulzer, David, Svenningsson, Per, Tanner, Caroline M., Carroll, Camille, Simon, David K., Brundin, Patrik
Format: Article
Language:English
Subjects:
Clinical trials
Epidemiology
Medical research
Movement disorders
Neurodegenerative diseases
Parkinson's disease
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 2011, the UK medical research charity Cure Parkinson’s set up the international Linked Clinical Trials (iLCT) committee to help expedite the clinical testing of potentially disease modifying therapies for Parkinson’s disease (PD). The first committee meeting was held at the Van Andel Institute in Grand Rapids, Michigan in 2012. This group of PD experts has subsequently met annually to assess and prioritize agents that may slow the progression of this neurodegenerative condition, using a systematic approach based on preclinical, epidemiological and, where possible, clinical data. Over the last 12 years, 171 unique agents have been evaluated by the iLCT committee, and there have been 21 completed clinical studies and 20 ongoing trials associated with the initiative. In this review, we briefly outline the iLCT process as well as the clinical development and outcomes of some of the top prioritized agents. We also discuss a few of the lessons that have been learnt, and we conclude with a perspective on what the next decade may bring, including the introduction of multi-arm, multi-stage clinical trial platforms and the possibility of combination therapies for PD.
ISSN:1877-7171
1877-718X
DOI:10.3233/JPD-230363